Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EBITDA (2020 - 2025)

Historic EBITDA for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$61.2 million.

  • 4D Molecular Therapeutics' EBITDA fell 1966.09% to -$61.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.4 million, marking a year-over-year decrease of 3682.41%. This contributed to the annual value of -$187.8 million for FY2024, which is 6642.69% down from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' EBITDA stood at -$61.2 million, which was down 1966.09% from -$59.5 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' EBITDA peaked at -$7.6 million during Q2 2021, and registered a low of -$61.2 million during Q3 2025.
  • Its 5-year average for EBITDA is -$34.5 million, with a median of -$30.1 million in 2023.
  • In the last 5 years, 4D Molecular Therapeutics' EBITDA soared by 4985.81% in 2021 and then tumbled by 27422.33% in 2022.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' EBITDA stood at -$24.8 million in 2021, then dropped by 15.97% to -$28.7 million in 2022, then dropped by 27.62% to -$36.7 million in 2023, then tumbled by 53.11% to -$56.1 million in 2024, then fell by 9.03% to -$61.2 million in 2025.
  • Its last three reported values are -$61.2 million in Q3 2025, -$59.5 million for Q2 2025, and -$53.6 million during Q1 2025.